The Chinese American Biopharmaceutical Society (CABS) K. Fong Award Committee is very pleased to announce that Dr. SCOTT LIU is the winner of the 2022 CABS K. Fong Award in Life Sciences for his outstanding contribution to the development of multiple biologic products from research to launch. We will honor Dr. Scott Liu at an award ceremony during the 22nd CABS Annual Meeting of the BioPacific Conference, on Saturday, November 12, 2022 at the San Mateo Marriott San Francisco Airport Hotel (1770 South Amphlett Blvd., San Mateo, CA 94402).
Scott Liu, PhD
Scott Liu is the Founder, Chairman, and CEO of HanchorBio Inc., a global biotechnology company pioneering the development of next-generation immunotherapies. As a life-science entrepreneur and successful biotech company-builder, Dr. Liu was one of the global partners of Fosun International Limited and Co-founder, President, and CEO of Shanghai Henlius Biotech Inc., a commercial-stage global biopharmaceutical company with the focus on high-quality, affordable, and innovative biologic medicines, listed on Hong Kong Stock Exchange (2696.HK) with a market value of over US$ 1.1 Billion. During his tenure with Henlius, Dr. Liu led multiple product development initiatives (over 30 biosimilars, novel monoclonal antibodies, and bispecific antibodies) and successfully launched 5 commercial monoclonal antibody products in China and Europe.
Dr. Liu has over 30 years of experience in managing corporate development, strategic portfolio, equity, cGMP quality operation, and CMC regulatory affairs. He has been instrumental in the development of the Technical Guidelines for the Research, Development and Evaluation of Biosimilars to promote globalization of the biopharmaceutical industry in China. Additionally, he has participated in development of multiple biological medicines, including Orencia® (for rheumatoid arthritis), Vectibix® (for colorectal cancer), Hanlikang® (rituximab biosimilar), Hanquyou®/Zercepac® (trastuzumab biosimilar), Handayuan® (adalimumab biosimilar), Hanbeitai® (bevacizumab biosimilar) and Hansizhuang® (serplulimab, novel anti-PD1).
Prior to founding HanchorBio and Henlius, Scott has previously served several executive positions such Vice President of Scientific Affairs at United Biomedical Inc., the Founding Director of the Biologics Quality Control Department at Bristol-Myers Squibb (Syracuse, USA), and the Director of Quality Analytical Laboratories at Amgen (Fremont, USA). Dr. Liu has authored or co-authored multiple scientific papers and has been an invited speaker in conferences with topics ranging from Biologics Process Development, Biomanufacturing, Oncology Biologics and Immuno-Oncology. He received his Ph.D. in biology at Purdue University and completed his post-doctoral training at Stanford University.
About CABS K. Fong Award in Life Sciences
CABS K. Fong Award in Life Sciences is presented annually to recognize those individuals who make significant contributions in life sciences and the biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life.
Candidates must be nominated by an active member of CABS. Selection criteria are based on candidate’s accomplishments in life sciences and contribution to the life science community, including one or all of the following:
- Proven achievements in therapeutic breakthroughs (including discovery, process or clinical development), diagnostics or research reagent/equipment markets.
- Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications.
- Significant contribution to the CABS community and promotion of international collaborations in life sciences.
About Dr. Kenneth Fong
Dr. Kenneth Fong has spent the last 32 years in the biotech industry after completing his academic pursuit in biomedical research.
He is best known for founding the biotech company, Clontech in 1984 which he built into one of the largest biomedical tool companies founded by an Asian American in the US (400 employees including 65 PhD scientists). Clontech was sold to Becton Dickinson in 1999 and Ken has continued his career as a Venture capitalist with Kenson Ventures that he founded. He has since cultivated more than 10 highly successful entrepreneurs, advising them and working with them on the growth of their companies.
Currently, he sits on the board of 4 biotech companies and he was intimately involved with the M/A and IPO of more than 10 companies that are worth more than $3 billion. These companies range from research tools, medical diagnostics and drug development. In almost all cases, Dr. Fong has been instrumental in providing strategies for sustainable growth, value creation and liquidity. Those successful entrepreneurs have moved on to assume leadership in other start-up and mid-sized companies, which in turn led to a new generation of entrepreneurs.
Ken has held a number of leadership positions over the years. He served as the President of the Society of Chinese Bioscientists in North America (2006-07) and President of the Bay Area Asian American Manufacturers' Association (AAMA, 1987). He was also a member of the Board of Trustees of the California State University System (2006-13). His philanthropic interests include scholarships to San Francisco State University, the Kenneth Fong-Hearst endowed scholarships to the CSU system and 40 student scholarships to Peking University. In 2006, he was involved with establishing the Fong Optometry and Medical library at UC Berkeley, and more recently an endowed professorship at Stanford University and a technology translation endowed fund at San Francisco State University.
Ken obtained his PhD from Indiana University and his BS from San Francisco State University.
Past recipients of CABS K. Fong Awards
2021：Dr. John O. Link, Vice President of Gilead Sciences and Dr. Xian-Ping Lu, Chairman, CEO of Shenzhen Chipscreen Biosciences Co. LTD, for their extraordinary achievements in research, entrepreneurship, and innovation.
2019: Dr. John V. Oyler, Chairman, Co-Found and CEO of BeiGene, for his entrepreneurship and business leadership to establish BeiGene as a world-class biopharmaceutical company.
2018: Dr. Yuling Luo, Founder, CEO and Chairman of Alamar Biosciences, and Dr. Guoliang Yu, Executive Chairman of Crown Bioscience, for their successful serial entrepreneurship in the life science business.
2017: Dr. Yinxiang Wang, Co-founder and CSO of Beta Pharma, for his role in leading development and commercialization of Conmana®, the first small molecule oncology drug specifically targeting cancer cells that was completely developed in China, and Dr. Edgar Engleman, for his pioneering research that was the basis of the Sipuleucel-T (Provenge) prostate cancer vaccine, the first active immunotherapy for cancer to be approved by the FDA.
2016: Dr. Gerald Chan, co-founder of Morningside, for his extraordinary vision and leadership in cultivating a generation of successful entrepreneurs and life sciences companies.
2015: Dr. Irving Weissman, of Stanford University, for his pioneering work in stem cell research.
2014: Dr. Ge Li, Founder and CEO of Wuxi Apptec, for creating and shaping the CRO business model in China and Dr. Hing L. Sham, formerly of Abbott for his leading role in the discovery of life- saving HIV protease inhibitors, ritonavir and Iopinavir.2013: Dr. Peter Hirth, Plexxikon & Sugen for his pivotal role in advancing 4 successful drugs to the market and Dr. Jean Cui, formerly of Pfizer for her role as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.